Taysha prices $187M stock offering; TSHA-102 achieves 100% milestone gain, FDA agrees on pivotal trial design

Taysha Gene Therapies, Inc.

Issued 46.9M shares at $2.75/sh and 25.9M pre-funded warrants at $2.749; net proceeds ~$187.4M.
Underwriters granted 30-day option for up to 10.9M additional shares; closing expected May 30.
TSHA-102 in Rett syndrome: 100% (10/10) patients gained/regained ≥1 milestone post-treatment, with high dose outperforming low dose.
FDA provided written alignment on single-arm pivotal Part B trial design; primary endpoint: developmental milestone gain/regain in patients ≥6 yrs.
Astellas option to license TSHA-102 remains exercisable 90 days after receipt of Rett Data Package expected mid-2025.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.